Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.48 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150608 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL2135258 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL20346208 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL709492 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL6938207 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL339332 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| Hydrochloric Acid SCHEMBL8452138 | 0.96 | GABRR1 (0.56) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| Hydrochloric Acid SCHEMBL8942934 | 0.96 | GABRR1 (0.56) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| Hydrochloric Acid SCHEMBL8942927 | 0.96 | GABRR1 (0.56) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| Hydrochloric Acid SCHEMBL8452135 | 0.96 | GABRR1 (0.56) | GABRR1SLC1A2SLC1A1GABRR2PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 206 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010757-A | Process for preparing trans-cyclobutane-1, 2-dicarboxamide | 海南长安国际制药有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-114835570-A | Synthesis method of trans-1, 2-diaminomethyl-cyclobutane and salt thereof | 上海寻科生物医药科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| US-20090286291-A1 | BORRELIDIN-PRODUCING POLYKETIDE SYNTHASE AND ITS USE | SALAS JOSE A | 2009-11-19 | — | — | US | claimed |
| EP-1961747-A2 | Borrelidin-producing polyketide synthase and its uses | Biotica Technology Limited (GB) | 2008-08-27 | — | — | EP | claimed |
| EP-1840216-A2 | Borrelidin-producing polyketides synthase and its uses | Biotica Technology Limited (GB) | 2007-10-03 | — | — | EP | claimed |
| EP-1576160-B8 | BORRELIDIN-DERIVATIVES AND THEIR USE IN MEDICINE | BIOTICA TECH LTD (GB) | 2007-06-27 | — | — | EP | claimed |
| US-20070065920-A1 | For treatment of microbial conditions (including malaria), proliferative disorders, inappropiate vascularisation, inhibition of angiogenesis; | THE UNIVERSITY OF OVIEDO (ES) | 2007-03-22 | — | — | US | claimed |
| EP-1576160-A2 | BORRELIDIN-PRODUCING POLYKETIDE SYNTHASE AND ITS USE | Biotica Technology Limited (GB) | 2005-09-21 | — | — | EP | claimed |
| WO-2004058976-A2 | BORRELIDIN-PRODUCING POLYKETIDE SYNTHASE AND ITS USE | BIOTICA TECHNOLOGY LIMITED (GB) | 2004-07-15 | — | — | WO | claimed |
| EP-0543264-B1 | Rewritable thermosensitive recording medium | TOPPAN PRINTING CO LTD (JP) | 1995-05-03 | — | — | EP | claimed |
| US-5278129-A | Low molecular weight alicyclic dicarboxylic acid | TOPPAN PRINTING CO., LTD. (JP) | 1994-01-11 | — | — | US | claimed |
| EP-0543264-A1 | Rewritable thermosensitive recording medium | Toppan Printing Co., Ltd. (JP) | 1993-05-26 | — | — | EP | claimed |
| EP-0130482-B1 | DIAMINOCYCLOHEXANE PLATINUM COMPLEXES, PROCESS FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Research Corporation (US) | 1988-12-28 | — | — | EP | claimed |
| US-4758588-A | Diaminocyclohexane platinum complexes | RESEARCH CORPORATION TECHNOLOGIES (US) | 1988-07-19 | — | — | US | claimed |
| US-4661516-A | WATER SOLUBLE, ANTITUMOR AGENTS | RESEARCH CORPORATION (US) | 1987-04-28 | — | — | US | claimed |
| EP-0130482-A1 | Diaminocyclohexane platinum complexes, process for preparing same and pharmaceutical compositions containing same | Research Corporation (US) | 1985-01-09 | — | — | EP | claimed |
| US-4230860-A | Processes for the separation of enantiomers by selective crystallization | AMERICAN CYANAMID COMPANY (US) | 1980-10-28 | — | — | US | claimed |
| CN-122029149-A | 3- (2- (Dimethylamino) ethyl) -1H-indol-4-yl oligoderivatives | 指南针探路者有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-3978101-A | HYDROGENATION CATALYSTS | RHONE-POULENC S.A. (FR) | 1976-08-31 | — | — | US | disclosed |
| US-3949000-A | COMPLEX FORMERS | RHONE-POULENC S.A. (FR) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065920-A1 | For treatment of microbial conditions (including malaria), proliferative disorders, inappropiate vascularisation, inhibition of angiogenesis; | COASY, FDPS, FLAD1 | GABRR1 3253/4885SLC1A2 4580/4885SLC1A1 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.